Efficacy and Safety of LCZ696A in Patients With Essential Hypertension
Status:
Completed
Trial end date:
2008-07-01
Target enrollment:
Participant gender:
Summary
This study was a dose-ranging efficiacy study in patients with essential hypertension to
assess the blood pressure lowering effect, and safety of LCZ696 compared to valsartan and
placebo. The study will also evaluate the efficacy and safety of AHU377 as compared to
placebo.
Phase:
Phase 2
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
LCZ 696 Sacubitril and valsartan sodium hydrate drug combination Valsartan